International Urogynecology Journal

, Volume 29, Issue 4, pp 489–495 | Cite as

Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence

  • Siri A. Mauseth
  • Svetlana Skurtveit
  • Arnulf Langhammer
  • Olav Spigset
Original Article


Introduction and hypothesis

The aims of this study were to investigate patterns of prescribing anticholinergic drugs among women with urinary incontinence (UI) and to identify factors associated with prescription of these drugs.


We analysed questionnaire data on UI from 21,735 women older than 20 years who participated in a cross-sectional population-based study in Nord-Trøndelag county, Norway (the HUNT study). These data were linked at the individual level to a national prescription database, and analysed using a multivariate logistic regression model.


Among the women with UI, 4.5% had been prescribed an anticholinergic drug during the previous 12 months. Prescription was most frequent in women with urge UI (10.5%) and mixed UI (7.0%). Of women with UI without treatment with an anticholinergic drug, 1.8% obtained such a prescription during the subsequent 12 months, corresponding to 3.1% of women with urge UI and 3.0% of women with mixed UI. Characteristics significantly associated with starting treatment were age above 50 years, urge or mixed UI, severe or very severe symptoms, consumption of four or more cups of coffee per day, and having visited a doctor for UI. No association was found with marital status, parity, smoking, alcohol, body mass index or anxiety/depression.


In this population-based study, 4.5% of women with UI were prescribed an anticholinergic drug, and the 12-month incidence of starting treatment was 1.8%. Age above 50 years, urge or mixed UI, severe symptoms, high coffee consumption and having visited a doctor for UI were factors associated with first-time drug prescription.


Anticholinergic drugs Drug treatment Epidemiology Health survey Prescription patterns Urinary incontinence 



This study was supported by a research grant from the Norwegian University of Science and Technology.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004;93(3):324–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Hunskaar S, Arnold EP, Burgio K, Diokno AC, Herzog AR, Mallett VT. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(5):301–19.CrossRefPubMedGoogle Scholar
  3. 3.
    Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of incontinence in the county of Nord-Trondelag. J Clin Epidemiol. 2000;53(11):1150–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.CrossRefPubMedGoogle Scholar
  5. 5.
    Epstein BJ, Gums JG, Molina E. Newer agents for the management of overactive bladder. Am Fam Physician. 2006;74(12):2061–8.PubMedGoogle Scholar
  6. 6.
    D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291–301.PubMedGoogle Scholar
  7. 7.
    Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(4):243–8.PubMedGoogle Scholar
  8. 8.
    Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health. 2005;8(4):495–505.CrossRefPubMedGoogle Scholar
  9. 9.
    Statistics from the Norwegian Prescription Database. 2017. Accessed 22 May 2017.
  10. 10.
    Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian prescription database. Acta Obstet Gynecol Scand. 2013;92(10):1208–15.PubMedGoogle Scholar
  11. 11.
    Ebbesen MH, Hunskaar S, Rortveit G, Hannestad YS. Prevalence, incidence and remission of urinary incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT). BMC Urol. 2013;13:27.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ebbesen MH, Hannestad YS, Midthjell K, Hunskaar S. Diabetes and urinary incontinence – prevalence data from Norway. Acta Obstet Gynecol Scand. 2007;86(10):1256–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT study. BJOG. 2003;110(3):247–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMedGoogle Scholar
  15. 15.
    Odeyemi IA, Dakin HA, O'Donnell RA, Warner J, Jacobs A, Dasgupta P. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract. 2006;60(8):949–58.CrossRefPubMedGoogle Scholar
  16. 16.
    Sandvik H, Seim A, Vanvik A, Hunskaar S. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. Neurourol Urodyn. 2000;19(2):137–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Sandvik H, Espuna M, Hunskaar S. Validity of the incontinence severity index: comparison with pad-weighing tests. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(5):520–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Felde G, Bjelland I, Hunskaar S. Anxiety and depression associated with incontinence in middle-aged women: a large Norwegian cross-sectional study. Int Urogynecol J. 2012;23(3):299–306.CrossRefPubMedGoogle Scholar
  19. 19.
    Felde G, Ebbesen MH, Hunskaar S. Anxiety and depression associated with urinary incontinence. A 10-year follow-up study from the Norwegian HUNT study (EPINCONT). Neurourol Urodyn. 2017;36(2):322–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Imamura M, Williams K, Wells M, McGrother C (2015) Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev. 2015;(12):CD003505.Google Scholar
  21. 21.
    Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW. Prevalence and natural history of female incontinence. Eur Urol. 1997;32(Suppl 2):3–12.PubMedGoogle Scholar
  22. 22.
    Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol. 2012;12:143.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The International Urogynecological Association 2017

Authors and Affiliations

  1. 1.Department of Clinical and Molecular Medicine, Faculty of Medicine and Health SciencesNorwegian University of Science and TechnologyTrondheimNorway
  2. 2.Department of PharmacoepidemiologyNorwegian Institute of Public HealthOsloNorway
  3. 3.Department of Public Health and Nursing and General Practice, Faculty of MedicineNorwegian University of Science and TechnologyTrondheimNorway
  4. 4.Department of Clinical PharmacologySt. Olav University HospitalTrondheimNorway

Personalised recommendations